单位：[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, National Clinical Research Center for Digestive Diseases, Beijing 100050, China临床科室国家中心消化分中心消化内科首都医科大学附属北京友谊医院[2]The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China[3]Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing 100050, China医技科室北京市临床医学研究所国家消化中心（方法学平台）首都医科大学附属北京友谊医院[4]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Disease, Beijing 100050, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院
Objective. The diagnostic value of antinuclear antibodies (ANAs) including anti-gp210 and anti-sp100 for primary biliary cholangitis/cirrhosis (PBC) has been widely reported. However, their diagnostic performances for antimitochondrial antibody- (AMA-) negative PBC were less well elucidated. Therefore, the aim of the current meta-analysis was to evaluate the diagnostic accuracy of ANAs in patients with AMA-negative PBC. Materials and Methods. Literature on the diagnostic value of biomarkers for AMA-negative PBC was systematically searched in PubMed, MEDLINE, EMBASE, and the Cochrane Library. The qualities of the retrieved studies were assessed by the Quality Assessment of Diagnostic Accuracy Studies-version 2 (QUADAS-2) scale. Pooled sensitivity and specificity of the biomarkers were calculated with random-effects models. The areas under the summary receiver operating characteristic (AUSROC) curves were used to evaluate the overall diagnostic performance of ANAs. Results. A total of 11 studies (400 AMA-negative PBC patients and 6217 controls) were finally included in the meta-analysis. ANAs had an overall sensitivity of 27% (95% CI: 20%, 35%) and specificity of 98% (95% CI: 97%, 99%). The pooled sensitivities for anti-gp210 and anti-sp100 were 23% (95% CI: 13%, 37%) and 25% (95% CI: 13%, 43%), respectively, and their specificities were 99% (95% CI: 97%, 100%) and 97% (95% CI: 93%, 98%), respectively. Conclusions. ANAs exhibited high specificity but low sensitivity and therefore could be used as reliable biomarkers to reduce the necessity of liver histology.
基金：
Digestive Medical Coordinated Development Center of the Beijing Municipal Administration of Hospitals [XXX0104, XXZ0203]; National Science and Technology Major Special Project for New Drug Development [2018ZX09201016]; National Science and Technology Major Special Project for Infectious Diseases [2018ZX10302204]
第一作者单位：[1]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, National Clinical Research Center for Digestive Diseases, Beijing 100050, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Qian Zhang,Zhiqiang Liu,Shanshan Wu,et al.Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis[J].GASTROENTEROLOGY RESEARCH and PRACTICE.2019,2019:doi:10.1155/2019/8959103.
APA：
Qian Zhang,Zhiqiang Liu,Shanshan Wu,Weijia Duan,Sha Chen...&Jidong Jia.(2019).Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.GASTROENTEROLOGY RESEARCH and PRACTICE,2019,
MLA：
Qian Zhang,et al."Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis".GASTROENTEROLOGY RESEARCH and PRACTICE 2019.(2019)
